Eyenovia to Participate in Two Upcoming Investor Conferences benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.
Share:
NEW YORK, May 10, 2021 (GLOBE NEWSWIRE) Eyenovia, Inc. (NASDAQ:EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics, today announced that the company has entered into a new $25 million credit financing facility with Silicon Valley Bank (SVB). This non-dilutive credit facility provides us with a significant amount of financial and operating flexibility at terms that we believe are favorable to the company, stated Dr. Sean Ianchulev, Chief Executive Officer and Chief Medical Officer of Eyenovia. These funds will assist us in preparing for our anticipated Mydcombi launch, advancing the development of MicroLine, as well as exploring additional ophthalmologic indications that could leverage our Optejet microdosing technology, all key elements of our long-term growth strategy.
Eyenovia Announces Appointment of Renowned Ophthalmologist and Scientific Leader Dr. Julia Haller to its Board of Directors
By
Staff
58 seconds ago
NEW YORK–(BUSINESS WIRE)–#EYEN Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic company developing a pipeline of advanced therapeutics based on its proprietary microdose array print (MAP™) platform technology, today announced the appointment of renowned ophthalmologist and scientific leader, Julia Haller, M.D., to its Board of Directors.
“We are delighted to welcome Dr. Haller to our Board of Directors at such an exciting time for Eyenovia,” commented Dr. Sean Ianchulev, Chief Executive Officer and Chief Medical Officer of Eyenovia. “We believe that Dr. Haller’s decades of experience as an esteemed ophthalmic surgeon, scientist, professor, and business leader will be invaluable to the Eyenovia team as we strive to advance our late-stage ophthalmic pipeline and work towards our near-term clinical and regulato
Hospital Vall d Hebron Investigators Publish Early Data on Anaconda Biomed s Mechanical Thrombectomy System for Ischemic Stroke
Initial single-center clinical study data
supporting
Anaconda Biomed s Advanced Neurovascular Access (ANA) Catheter System for the treatment of ischemic stroke have been published in the Journal of Neuroradiology by investigators at Hospital Vall d Hebron in Barcelona.
The hospital is participating in the multi-center SOLONDA ( SOL itaire in combination with the ANA Catheter system manufactured by Anac ONDA ) clinical trial, a 125-patient, prospective study that will assess system safety and reperfusion measured using the modified treatment in cerebral infarction (mTICI) score.
Hospital Vall d Hebron investigators followed 35 consecutive patients, with published results as follows: